Cargando…

TAM Infiltration Differences in “Tumor-First” and “ZHENG-First” Models and the Underlying Inflammatory Molecular Mechanism in Pancreatic Cancer

Background: Syndrome (ZHENG in Chinese) in traditional Chinese medicine (TCM) refers to the intrinsic characteristics of a pathological process at a certain stage; these characteristics are influenced by internal and external environments and reveal the nature of a disease. Proper syndrome different...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Feng-Jiao, Wang, Peng, Chen, Lian-Yu, Geng, Ya-Wen, Chen, Hao, Meng, Zhi-Qiang, Liu, Lu-Ming, Chen, Zhen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6142096/
https://www.ncbi.nlm.nih.gov/pubmed/29681184
http://dx.doi.org/10.1177/1534735418771193
_version_ 1783355805640163328
author Wang, Feng-Jiao
Wang, Peng
Chen, Lian-Yu
Geng, Ya-Wen
Chen, Hao
Meng, Zhi-Qiang
Liu, Lu-Ming
Chen, Zhen
author_facet Wang, Feng-Jiao
Wang, Peng
Chen, Lian-Yu
Geng, Ya-Wen
Chen, Hao
Meng, Zhi-Qiang
Liu, Lu-Ming
Chen, Zhen
author_sort Wang, Feng-Jiao
collection PubMed
description Background: Syndrome (ZHENG in Chinese) in traditional Chinese medicine (TCM) refers to the intrinsic characteristics of a pathological process at a certain stage; these characteristics are influenced by internal and external environments and reveal the nature of a disease. Proper syndrome differentiation is the basic principle that guides clinical treatment. Objective: To have a good understanding of tumor progression and the different mechanisms related to ZHENG that have occurred before and after tumor development and to explore the valid evaluation criteria of different pancreatic cancer syndromes to improve the guiding role of TCM syndrome differentiation in pancreatic cancer treatment. Methods: In this study, we established mouse subcutaneous pancreatic cancer models, namely, Con (control), Pi-Xu (Spleen-Deficiency), Shi-Re (Dampness-Heat), and Xue-Yu (Blood-Stasis). Then, for the first time, we compared the different effects of “ZHENG-first” (referring to a different disease status that occurred before tumor occurrence) and “Tumor-first” (referring to the change in the tumor microenvironment and the resulting changes in the state of the body) conditions on tumor progression and evaluated the associated molecular mechanisms. Results: We found that tumor growth in the “ZHENG-first” and “Tumor-first” conditions was different. In the “Tumor-first” model, the tumor growth in the Pi-Xu group was faster than that in the other groups. However, in the “ZHENG-first” model, the tumor growth trend was most obvious in the Shi-Re group. There was a difference in tumor-associated macrophage infiltration between the 2 models. The expression levels of the inflammatory cytokines IL-6, IL-10, and P-STAT3 were also differentially altered. Conclusion: The emergence of ZHENG conditions before or after tumor occurrence had different impacts on pancreatic cancer development, and these impacts may be related to differences in tumor-associated macrophage infiltration and the involved inflammatory cytokines IL-6, IL-10, and P-STAT3. The study results uncovered the molecular basis of syndrome differentiation in pancreatic cancer progression, which might provide more specific guidance for TCM treatment of pancreatic cancer.
format Online
Article
Text
id pubmed-6142096
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-61420962018-09-20 TAM Infiltration Differences in “Tumor-First” and “ZHENG-First” Models and the Underlying Inflammatory Molecular Mechanism in Pancreatic Cancer Wang, Feng-Jiao Wang, Peng Chen, Lian-Yu Geng, Ya-Wen Chen, Hao Meng, Zhi-Qiang Liu, Lu-Ming Chen, Zhen Integr Cancer Ther Research Articles Background: Syndrome (ZHENG in Chinese) in traditional Chinese medicine (TCM) refers to the intrinsic characteristics of a pathological process at a certain stage; these characteristics are influenced by internal and external environments and reveal the nature of a disease. Proper syndrome differentiation is the basic principle that guides clinical treatment. Objective: To have a good understanding of tumor progression and the different mechanisms related to ZHENG that have occurred before and after tumor development and to explore the valid evaluation criteria of different pancreatic cancer syndromes to improve the guiding role of TCM syndrome differentiation in pancreatic cancer treatment. Methods: In this study, we established mouse subcutaneous pancreatic cancer models, namely, Con (control), Pi-Xu (Spleen-Deficiency), Shi-Re (Dampness-Heat), and Xue-Yu (Blood-Stasis). Then, for the first time, we compared the different effects of “ZHENG-first” (referring to a different disease status that occurred before tumor occurrence) and “Tumor-first” (referring to the change in the tumor microenvironment and the resulting changes in the state of the body) conditions on tumor progression and evaluated the associated molecular mechanisms. Results: We found that tumor growth in the “ZHENG-first” and “Tumor-first” conditions was different. In the “Tumor-first” model, the tumor growth in the Pi-Xu group was faster than that in the other groups. However, in the “ZHENG-first” model, the tumor growth trend was most obvious in the Shi-Re group. There was a difference in tumor-associated macrophage infiltration between the 2 models. The expression levels of the inflammatory cytokines IL-6, IL-10, and P-STAT3 were also differentially altered. Conclusion: The emergence of ZHENG conditions before or after tumor occurrence had different impacts on pancreatic cancer development, and these impacts may be related to differences in tumor-associated macrophage infiltration and the involved inflammatory cytokines IL-6, IL-10, and P-STAT3. The study results uncovered the molecular basis of syndrome differentiation in pancreatic cancer progression, which might provide more specific guidance for TCM treatment of pancreatic cancer. SAGE Publications 2018-04-22 /pmc/articles/PMC6142096/ /pubmed/29681184 http://dx.doi.org/10.1177/1534735418771193 Text en © The Author(s) 2018 http://www.creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Research Articles
Wang, Feng-Jiao
Wang, Peng
Chen, Lian-Yu
Geng, Ya-Wen
Chen, Hao
Meng, Zhi-Qiang
Liu, Lu-Ming
Chen, Zhen
TAM Infiltration Differences in “Tumor-First” and “ZHENG-First” Models and the Underlying Inflammatory Molecular Mechanism in Pancreatic Cancer
title TAM Infiltration Differences in “Tumor-First” and “ZHENG-First” Models and the Underlying Inflammatory Molecular Mechanism in Pancreatic Cancer
title_full TAM Infiltration Differences in “Tumor-First” and “ZHENG-First” Models and the Underlying Inflammatory Molecular Mechanism in Pancreatic Cancer
title_fullStr TAM Infiltration Differences in “Tumor-First” and “ZHENG-First” Models and the Underlying Inflammatory Molecular Mechanism in Pancreatic Cancer
title_full_unstemmed TAM Infiltration Differences in “Tumor-First” and “ZHENG-First” Models and the Underlying Inflammatory Molecular Mechanism in Pancreatic Cancer
title_short TAM Infiltration Differences in “Tumor-First” and “ZHENG-First” Models and the Underlying Inflammatory Molecular Mechanism in Pancreatic Cancer
title_sort tam infiltration differences in “tumor-first” and “zheng-first” models and the underlying inflammatory molecular mechanism in pancreatic cancer
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6142096/
https://www.ncbi.nlm.nih.gov/pubmed/29681184
http://dx.doi.org/10.1177/1534735418771193
work_keys_str_mv AT wangfengjiao taminfiltrationdifferencesintumorfirstandzhengfirstmodelsandtheunderlyinginflammatorymolecularmechanisminpancreaticcancer
AT wangpeng taminfiltrationdifferencesintumorfirstandzhengfirstmodelsandtheunderlyinginflammatorymolecularmechanisminpancreaticcancer
AT chenlianyu taminfiltrationdifferencesintumorfirstandzhengfirstmodelsandtheunderlyinginflammatorymolecularmechanisminpancreaticcancer
AT gengyawen taminfiltrationdifferencesintumorfirstandzhengfirstmodelsandtheunderlyinginflammatorymolecularmechanisminpancreaticcancer
AT chenhao taminfiltrationdifferencesintumorfirstandzhengfirstmodelsandtheunderlyinginflammatorymolecularmechanisminpancreaticcancer
AT mengzhiqiang taminfiltrationdifferencesintumorfirstandzhengfirstmodelsandtheunderlyinginflammatorymolecularmechanisminpancreaticcancer
AT liuluming taminfiltrationdifferencesintumorfirstandzhengfirstmodelsandtheunderlyinginflammatorymolecularmechanisminpancreaticcancer
AT chenzhen taminfiltrationdifferencesintumorfirstandzhengfirstmodelsandtheunderlyinginflammatorymolecularmechanisminpancreaticcancer